The dosage calculator helps you model these scenarios
T2DM was the most common diagnosis in incident patients overall (60.0%) and between the years 2019 and 2022
Knowing what to expect helps you stay committed to your weight loss plan
Therapeutic advances in drug safety 2025
Based on available Phase 2 trial data, the side effect profile of retatrutide shares similarities with other GLP-1 receptor agonists, as reflected in the Summary of Product Characteristics (SmPC) for approved agents such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro)
Although the role of NKCC2 in renal handling of glucose remains poorly defined, NKCC2A KO mice developed several aspects of MetS including increased basal glycemia, glucose intolerance and insulin resistance (Kelly et al., 2019), but not hypertension, at least when mice were young (Oppermann et al., 2007)